Evidence map›Paper›PMID 40213004›Full record

ArticleSmall science2024

Poly(ethylene Glycol) (PEG)-OligoRNA Hybridization to mRNA Enables Fine-Tuned Polyplex PEGylation for Spleen-Targeted mRNA Delivery.

Miki Suzuki, Yuki Mochida, Mao Hori, Akimasa Hayashi, Kazuko Toh, Theofilus A Tockary, Xueying Liu, Victor Marx, Hidetomo Yokoo, Kanjiro Miyata and 2 more

Abstract read
In one paragraph

Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Miki SuzukiMedical Chemistry Graduate School of Medical Science Kyoto Prefectural University of Medicine 1-5 Shimogamohangi-cho, Sakyo-ku Kyoto 606-0823 Japan.
Yuki MochidaDepartment of Advanced Nanomedical Engineering Medical Research Institute Tokyo Medical and Dental University (TMDU) 1-5-45 Yushima, Bunkyo-ku Tokyo 113-8510 Japan.
Mao HoriDepartment of Materials Engineering Graduate School of Engineering The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8656 Japan.
Akimasa HayashiDepartment of Pathology Kyorin University School of Medicine 6-20-2 Shinkawa, Mitaka-shi Tokyo 181-8611 Japan.
Kazuko TohInnovation Center of NanoMedicine (iCONM) Kawasaki Institute of Industrial Promotion 3-25-14 Tonomachi, Kawasaki-ku Kawasaki 210-0821 Japan.
Theofilus A TockaryInnovation Center of NanoMedicine (iCONM) Kawasaki Institute of Industrial Promotion 3-25-14 Tonomachi, Kawasaki-ku Kawasaki 210-0821 Japan.
Xueying LiuInnovation Center of NanoMedicine (iCONM) Kawasaki Institute of Industrial Promotion 3-25-14 Tonomachi, Kawasaki-ku Kawasaki 210-0821 Japan.
Victor MarxMedical Chemistry Graduate School of Medical Science Kyoto Prefectural University of Medicine 1-5 Shimogamohangi-cho, Sakyo-ku Kyoto 606-0823 Japan.
Hidetomo YokooMedical Chemistry Graduate School of Medical Science Kyoto Prefectural University of Medicine 1-5 Shimogamohangi-cho, Sakyo-ku Kyoto 606-0823 Japan.
Kanjiro MiyataDepartment of Materials Engineering Graduate School of Engineering The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113-8656 Japan.
Makoto ObaMedical Chemistry Graduate School of Medical Science Kyoto Prefectural University of Medicine 1-5 Shimogamohangi-cho, Sakyo-ku Kyoto 606-0823 Japan.
Satoshi UchidaMedical Chemistry Graduate School of Medical Science Kyoto Prefectural University of Medicine 1-5 Shimogamohangi-cho, Sakyo-ku Kyoto 606-0823 Japan.ORCID https://orcid.org/0000-0001-8726-0478

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organ-selective targeting of mRNA polyplexes has been rarely explored despite the substantial potential of polymer-based systems in mRNA delivery. In this study, spleen-selective delivery of polyplexes is achieved by employing mRNA engineering to coat them with poly(ethylene glycol) (PEG). In this approach, mRNA is hybridized with PEGylated complementary RNA oligonucleotides (PEG-OligoRNAs), followed by the addition of linear poly(ethyleneimine). In this method, it is ensured that nearly all added PEG strands bind to the polyplexes, thereby enabling precise control of PEG amounts on the surface. Following systemic injection into mice, non-PEGylated polyplexes yield robust protein expression in the lung and spleen. Intriguingly, adding a small number of PEG-OligoRNAs drastically reduces protein expression efficiency in the lung while preserving it in the spleen, realizing spleen targeting of mRNA polyplexes. Furthermore, PEGylated polyplexes demonstrate their potential utility in mRNA vaccination. In mechanistic analyses, non-PEGylated polyplexes immediately agglomerate in the blood and deposit in the lung. Coating polyplexes with a small amount of short PEG effectively prevents these processes. Notably, even slight changes in PEG amounts and lengths dramatically impact the physicochemical properties and biological functionalities of the polyplexes, emphasizing the benefits of an mRNA engineering-based approach for fine-tuning polyplex PEG coating.

Indexed as

intravital imagingsmRNA deliveriesmRNA engineeringspolyplexestissue targetings

Identifiers

PMID40213004
PMCPMC11935287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.